We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
ARIUS Announces Manufacturing Agreement with Avid Bioservices for CD44 Cancer Stem Cell Antibody
News

ARIUS Announces Manufacturing Agreement with Avid Bioservices for CD44 Cancer Stem Cell Antibody

ARIUS Announces Manufacturing Agreement with Avid Bioservices for CD44 Cancer Stem Cell Antibody
News

ARIUS Announces Manufacturing Agreement with Avid Bioservices for CD44 Cancer Stem Cell Antibody

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "ARIUS Announces Manufacturing Agreement with Avid Bioservices for CD44 Cancer Stem Cell Antibody"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

ARIUS Research Inc. announced that it has entered into a manufacturing supply and technology transfer agreement for its CD44 Cancer Stem Cell antibody with Avid Bioservices.

Avid has begun manufacturing a supply of the drug for human clinical trials which ARIUS plans to initiate in 2008. ARIUS also announced it has scheduled a pre-IND meeting with the FDA that will take place in January.

"The initiation of manufacturing and the scheduling of our pre-IND meeting with the FDA in January reflect the significant progress we have made with our CD44 Cancer Stem Cell program," said Dr. David Young, President and Chief Executive Officer of ARIUS.

"Avid has proven expertise in the scale-up and manufacture of clinical and commercial grade antibodies and will provide us with a supply of our CD44 targeting drug to initiate human clinical trials in 2008, subject to the clearance of our IND by the FDA."

"This new manufacturing agreement is the result of the solid working relationship we have developed with the ARIUS team," said F. David King, Vice President, Business Development of Avid.

"Our goal is to form strategic partnerships with innovative life sciences companies like ARIUS, serving as a premier service provider by seamlessly integrating our experience and capabilities with our clients' needs."

Advertisement